BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Borensztajn K, von der Thüsen JH, Peppelenbosch MP, Spek CA. The coagulation factor Xa/protease activated receptor-2 axis in the progression of liver fibrosis: a multifaceted paradigm. J Cell Mol Med 2010;14:143-53. [PMID: 19968736 DOI: 10.1111/j.1582-4934.2009.00980.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
Number Citing Articles
1 Mußbach F, Ungefroren H, Günther B, Katenkamp K, Henklein P, Westermann M, Settmacher U, Lenk L, Sebens S, Müller JP, Böhmer FD, Kaufmann R. Proteinase-activated receptor 2 (PAR2) in hepatic stellate cells - evidence for a role in hepatocellular carcinoma growth in vivo. Mol Cancer 2016;15:54. [PMID: 27473374 DOI: 10.1186/s12943-016-0538-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
2 Cisowski J, O’Callaghan K, Kuliopulos A, Yang J, Nguyen N, Deng Q, Yang E, Fogel M, Tressel S, Foley C. Targeting protease-activated receptor-1 with cell-penetrating pepducins in lung cancer. Am J Pathol. 2011;179:513-523. [PMID: 21703428 DOI: 10.1016/j.ajpath.2011.03.025] [Cited by in Crossref: 59] [Cited by in F6Publishing: 50] [Article Influence: 5.4] [Reference Citation Analysis]
3 Dhar A, Sadiq F, Anstee QM, Levene AP, Goldin RD, Thursz MR. Thrombin and factor Xa link the coagulation system with liver fibrosis. BMC Gastroenterol. 2018;18:60. [PMID: 29739329 DOI: 10.1186/s12876-018-0789-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
4 Knight V, Tchongue J, Lourensz D, Tipping P, Sievert W. Protease-activated receptor 2 promotes experimental liver fibrosis in mice and activates human hepatic stellate cells. Hepatology 2012;55:879-87. [PMID: 22095855 DOI: 10.1002/hep.24784] [Cited by in Crossref: 56] [Cited by in F6Publishing: 56] [Article Influence: 5.6] [Reference Citation Analysis]
5 Mercer PF, Chambers RC. Coagulation and coagulation signalling in fibrosis. Biochim Biophys Acta 2013;1832:1018-27. [PMID: 23298546 DOI: 10.1016/j.bbadis.2012.12.013] [Cited by in Crossref: 59] [Cited by in F6Publishing: 56] [Article Influence: 6.6] [Reference Citation Analysis]
6 Sun Q, Wang Y, Zhang J, Lu J. ENMD-1068 inhibits liver fibrosis through attenuation of TGF-β1/Smad2/3 signaling in mice. Sci Rep 2017;7:5498. [PMID: 28710422 DOI: 10.1038/s41598-017-05190-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
7 Dhar A, Mullish BH, Thursz MR. Anticoagulation in chronic liver disease. J Hepatol. 2017;66:1313-1326. [PMID: 28088580 DOI: 10.1016/j.jhep.2017.01.006] [Cited by in Crossref: 30] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
8 Lin C, von der Thüsen J, Daalhuisen J, ten Brink M, Crestani B, van der Poll T, Borensztajn K, Spek CA. Pharmacological Targeting of Protease-Activated Receptor 2 Affords Protection from Bleomycin-Induced Pulmonary Fibrosis. Mol Med 2015;21:576-83. [PMID: 26147947 DOI: 10.2119/molmed.2015.00094] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
9 Shearer AM, Rana R, Austin K, Baleja JD, Nguyen N, Bohm A, Covic L, Kuliopulos A. Targeting Liver Fibrosis with a Cell-penetrating Protease-activated Receptor-2 (PAR2) Pepducin. J Biol Chem 2016;291:23188-98. [PMID: 27613872 DOI: 10.1074/jbc.M116.732743] [Cited by in Crossref: 27] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
10 Anwar MM, Sah R, Shrestha S, Ozaki A, Roy N, Fathah Z, Rodriguez-Morales AJ. Disengaging the COVID-19 Clutch as a Discerning Eye Over the Inflammatory Circuit During SARS-CoV-2 Infection. Inflammation 2022. [PMID: 35639261 DOI: 10.1007/s10753-022-01674-5] [Reference Citation Analysis]
11 Posthuma JJ, Posma JJN, Schep G, Bender MMH, van Oerle R, van der Wal AC, Ten Cate H, Spronk HMH. Protease-activated receptors are potential regulators in the development of arterial endofibrosis in high-performance athletes. J Vasc Surg 2019;69:1243-50. [PMID: 30314721 DOI: 10.1016/j.jvs.2018.05.220] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
12 Rybinski B, Franco-Barraza J, Cukierman E. The wound healing, chronic fibrosis, and cancer progression triad. Physiol Genomics 2014;46:223-44. [PMID: 24520152 DOI: 10.1152/physiolgenomics.00158.2013] [Cited by in Crossref: 124] [Cited by in F6Publishing: 107] [Article Influence: 15.5] [Reference Citation Analysis]
13 Pant A, Kopec AK, Luyendyk JP. Role of the blood coagulation cascade in hepatic fibrosis. Am J Physiol Gastrointest Liver Physiol 2018;315:G171-6. [PMID: 29723040 DOI: 10.1152/ajpgi.00402.2017] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
14 Vilaseca M, García-Calderó H, Lafoz E, García-Irigoyen O, Avila MA, Reverter JC, Bosch J, Hernández-Gea V, Gracia-Sancho J, García-Pagán JC. The anticoagulant rivaroxaban lowers portal hypertension in cirrhotic rats mainly by deactivating hepatic stellate cells. Hepatology 2017;65:2031-44. [PMID: 28142199 DOI: 10.1002/hep.29084] [Cited by in Crossref: 44] [Cited by in F6Publishing: 37] [Article Influence: 8.8] [Reference Citation Analysis]
15 Park YS, Park CM, Lee HJ, Goo JM, Chung DH, Lee SM, Yim JJ, Kim YW, Han SK, Yoo CG. Clinical implication of protease-activated receptor-2 in idiopathic pulmonary fibrosis. Respir Med 2013;107:256-62. [PMID: 23131707 DOI: 10.1016/j.rmed.2012.10.011] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
16 Borkham-kamphorst E, Zimmermann HW, Gassler N, Bissels U, Bosio A, Tacke F, Weiskirchen R, Kanse SM. Factor VII activating protease (FSAP) exerts anti-inflammatory and anti-fibrotic effects in liver fibrosis in mice and men. Journal of Hepatology 2013;58:104-11. [DOI: 10.1016/j.jhep.2012.09.007] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
17 Kavanagh C, Shaw S, Webster CR. Coagulation in hepatobiliary disease. J Vet Emerg Crit Care (San Antonio). 2011;21:589-604. [PMID: 22316251 DOI: 10.1111/j.1476-4431.2011.00691.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 3.2] [Reference Citation Analysis]
18 Cerini F, Vilaseca M, Lafoz E, García-Irigoyen O, García-Calderó H, Tripathi DM, Avila M, Reverter JC, Bosch J, Gracia-Sancho J. Enoxaparin reduces hepatic vascular resistance and portal pressure in cirrhotic rats. J Hepatol. 2016;64:834-842. [PMID: 26686269 DOI: 10.1016/j.jhep.2015.12.003] [Cited by in Crossref: 63] [Cited by in F6Publishing: 57] [Article Influence: 9.0] [Reference Citation Analysis]
19 Ahmed IA, Jaffa MA, Moussa M, Hatem D, El-Achkar GA, Al Sayegh R, Karam M, Hamade E, Habib A, Jaffa AA. Plasma Kallikrein as a Modulator of Liver Injury/Remodeling. Front Pharmacol 2021;12:715111. [PMID: 34566641 DOI: 10.3389/fphar.2021.715111] [Reference Citation Analysis]
20 Shouman MM, Abdelsalam RM, Tawfick MM, Kenawy SA, El-Naa MM. Antisense Tissue Factor Oligodeoxynucleotides Protected Diethyl Nitrosamine/Carbon Tetrachloride-Induced Liver Fibrosis Through Toll Like Receptor4-Tissue Factor-Protease Activated Receptor1 Pathway. Front Pharmacol 2021;12:676608. [PMID: 34045968 DOI: 10.3389/fphar.2021.676608] [Reference Citation Analysis]
21 Lu J, Chen B, Li S, Sun Q. Tryptase inhibitor APC 366 prevents hepatic fibrosis by inhibiting collagen synthesis induced by tryptase/protease-activated receptor 2 interactions in hepatic stellate cells. Int Immunopharmacol. 2014;20:352-357. [PMID: 24735816 DOI: 10.1016/j.intimp.2014.04.001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]